Key Takeaways:
Rosen Law Firm announced on April 10 an investigation into potential securities claims against Immutep Ltd. (NASDAQ: IMMP), following allegations the company may have issued materially misleading business information to the public.
"If you purchased Immutep securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement," the firm stated, encouraging affected investors to contact them for information on the class action.
The New York-based law firm is preparing a class action to seek recovery of investor losses. The investigation centers on whether Immutep provided false or misleading statements regarding its business operations, although specific details of the allegations or the financial impact have not yet been disclosed. Stock price reaction to the announcement was not immediately available.
The announcement of a securities investigation can often precede a formal class-action lawsuit, which poses significant financial and reputational risks for a publicly-traded company. The probe creates uncertainty for Immutep shareholders and could lead to stock price volatility.
Rosen Law Firm represents investors globally, focusing on securities class actions and shareholder derivative litigation. According to ISS Securities Class Action Services, the firm was ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top four each year since 2013, recovering hundreds of millions of dollars for investors.
The investigation puts Immutep's recent disclosures under scrutiny, with potential legal proceedings to follow. Investors will be watching for the formal filing of a class action lawsuit, which would provide specific details of the allegations against the company.
This article is for informational purposes only and does not constitute investment advice.
